Nilotinib Zentiva

Nilotinib, the active ingredient in Nilotinib Zentiva, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia, including Philadelphia chromosome‑positive disease, in adult patients.\n\nGNH India supplies Nilotinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is a targeted therapy used in the management of chronic myeloid leukemia, a disease driven by BCR‑ABL tyrosine‑kinase activity.\n\n- Chronic myeloid leukemia (CML): achieves cytogenetic and molecular remission by inhibiting leukemic cell proliferation.\n- Philadelphia chromosome‑positive CML: blocks the BCR‑ABL fusion protein that drives disease progression.\n- Accelerated‑phase CML: provides disease control when standard therapy is insufficient.

Adverse reactions may occur with Nilotinib therapy.\n\nCommon Side Effects:\n- Nausea: mild to moderate upset stomach.\n- Diarrhea: loose stools, usually transient.\n- Rash: skin erythema or pruritus.\n- Fatigue: reduced energy levels.\n\nSerious or Rare Side Effects:\n- QT interval prolongation: may predispose to cardiac arrhythmias.\n- Pancreatitis: inflammation of the pancreas requiring medical attention.\n- Hepatic toxicity: elevated liver enzymes or hepatitis.\n- Severe neutropenia or thrombocytopenia: marked reduction in white blood cells or platelets.

Patients should be monitored for specific safety concerns before and during treatment with Nilotinib.\n\n- Cardiac monitoring: obtain baseline ECG and repeat if symptoms arise.\n- QT prolongation: avoid concomitant drugs that lengthen QT interval.\n- Hepatic function: check liver enzymes regularly.\n- Pancreatic enzymes: monitor amylase and lipase levels.\n- Pregnancy risk: contraindicated in pregnancy; use effective contraception.\n- Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct light.

Nilotinib may interact with other medicines, altering its effectiveness or safety profile.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase Nilotinib exposure.\n- Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce Nilotinib levels.\n- Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously.\n\nModerate Interactions (Monitor Closely):\n- Proton‑pump inhibitors (e.g., omeprazole): may modestly lower drug concentration.\n- Statins metabolized by CYP3A4 (e.g., simvastatin): risk of increased statin exposure; consider dose adjustment.